Page last updated: 2024-08-23

paclitaxel and Hematologic Diseases

paclitaxel has been researched along with Hematologic Diseases in 137 studies

Research

Studies (137)

TimeframeStudies, this research(%)All Research%
pre-19901 (0.73)18.7374
1990's28 (20.44)18.2507
2000's75 (54.74)29.6817
2010's30 (21.90)24.3611
2020's3 (2.19)2.80

Authors

AuthorsStudies
Ayari, J; Balti, M; Ben Abdallah, I; Ben Hassen, M; Ben Nasr, S; Doghri, Y; Fendri, S; Haddaoui, A; Trigui, E; Zribi, A1
Aghajanian, C; Armstrong, DK; Bell-McGuinn, KM; Chen, A; Duska, LR; Fracasso, PM; Gillen, J; Gordon, SW; Gray, HJ; Guntupalli, SR; Hagemann, AR; Hays, J; Mathews, CA; Miller, A; Moore, KN; O'Cearbhaill, R; Schilder, RJ; Walker, JL1
Exner, F; Flentje, M; Höcht, S; Kleine, P; Mantel, F; Müller, E; Polat, B; Richter, A; Ströhle, S; Weick, S; Zimmermann, M1
Boban, T; Boraska Jelavić, T; Brčić, L; Vrdoljak, E1
Du, D; Fang, M; Song, T; Wu, S; Zhang, X1
Allan, E; Ayan, A; Barney, CL; Bazan, JG; DiCostanzo, D; Grecula, J; Haglund, KE; Otterson, GA; Scoville, N; Williams, T; Xu-Welliver, M1
Alazraki, AL; Amankwah, EK; Cash, T; Clark, D; George, BA; Metts, JL; Olson, TA; Wasilewski-Masker, KJ1
Chen, YH; Huang, ST; Li, WS; Lin, CT; Wang, YP; Wu, HC1
Bian, NN; Min, GT; Wang, YH1
Benedetti Panici, P; Boccia, SM; Di Donato, V; Di Mauro, F; Giancotti, A; Musacchio, L; Muzii, L; Palaia, I; Perniola, G; Tomao, F1
Hasegawa, R; Imaizumi, H; Iwai, T; Kaneko, T; Kawaguchi, Y; Kida, M; Koizumi, W; Kurosu, T; Matsumoto, T; Miyata, E; Ohno, T; Okuwaki, K; Uehara, K; Watanabe, M; Yamauchi, H1
Belau, A; Braicu, I; Ehmke, M; Koehler, G; Koensgen, D; Ledwon, P; Lichtenegger, W; Markmann, S; Mustea, A; Scharf, JP; Schneidewind, L; Sehouli, J; Sommer, H; Zygmunt, M1
Gao, X; Jing, T; Sun, Y; Wang, F; Xu, C; Zhang, C1
Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H1
Bekaii-Saab, T; Kleiber, B; Lustberg, MB; Mikhail, S; Monk, P; Mortazavi, A; Ruppert, AS; Villalona-Calero, M1
Ajgal, Z; Alexandre, J; Boudou-Rouquette, P; Cessot, A; Chapuis, N; Emile, G; Fontenay, M; Goldwasser, F; Huillard, O; Tigaud, JM1
Fujiwara, Y; Giranda, V; Hashiba, H; Horinouchi, H; Kanda, S; Kitazono, S; Mizugaki, H; Nokihara, H; Qian, J; Shepherd, SP; Tamura, T; Xiong, H; Yagishita, S; Yamamoto, N1
Boven, E; Frederiks, CN; Guchelaar, HJ; Lam, SW1
Ahmed, I; Aisner, J; Benenati, B; Chen, T; Deek, MP; Jabbour, SK; Kim, S; Zou, W1
Batista, N; Gonzalez-de-la-Fuente, GA; Gutierrez, F; Nazco, GJ; Oramas, J1
Baron, MH; Bessette, P; Colombo, A; Creutzberg, CL; de Boer, SM; Fyles, A; Haie-Meder, C; Katsaros, D; Khaw, P; Kitchener, HC; Kruitwagen, RF; Ledermann, JA; Mileshkin, L; Nijman, HW; Nout, RA; Ottevanger, PB; Powell, ME; Putter, H; Smit, VT; Verhoeven-Adema, KW1
Chllamma, MK; Cook, N; Dhani, NC; Dodd, A; Giby, K; Hedley, DW; Knox, JJ; Moore, MJ; Wang, L1
Kamimura, K; Matsumoto, Y; Moriyama, M; Saijo, Y; Zhou, Q1
Arbea, L; Cano, D; Ceniceros, L; Chopitea, A; Diaz-Gonzalez, JA; Hernandez, JL; Iragorri, Y; Legaspi, J; Martin-Romano, P; Martínez-Regueira, F; Ponz-Sarvise, M; Rodríguez, J; Sola, JJ; Subtil, JC1
Dhanikula, AB; Dhanikula, RS; Panchagnula, R1
Eggemann, H; Elling, D; Harbeck, N; Janni, W; Kaufmann, M; Kiechle, M; Kümmel, S; Loibl, S; Nekljudova, V; Sommer, H; von Minckwitz, G1
Bagnardi, V; Balduzzi, A; Bertolini, F; Cardillo, A; Colleoni, M; Goldhirsch, A; Mancuso, P; Montagna, E; Orlando, L; Scarano, E; Torrisi, R; Veronesi, P; Viale, G1
Bordin, V; Bozzoni, S; Caldiera, S; Codecà, C; Di Maria, G; Ferrari, D; Fiore, J; Floriani, I; Foa, P; Luciani, A; Zonato, S1
Fracasso, PM; Garcia, AA; Knight, D; Mannel, RS; Muggia, F; Sill, MW; Swensen, R; Tiersten, AD; Warshal, DP1
Adams, G; Green, JA; Walking, J; Wong, H; Zekri, J1
Clawson, A; Iglesias, J; Krekow, L; O'Shaughnessy, J; Robert, N; Stokoe, C1
Blumenschein, GR; Chao, RC; Cohen, RB; Heath, EI; Kim, ST; Loconte, NK; Lorusso, PM; Ruiz-Garcia, A; Wilding, G1
Ando, M; Hasegawa, Y; Isa, S; Kawaguchi, T; Kubo, A; Nakagawa, K; Ou, SH; Shiraishi, J; Takada, M; Tsuji, T; Tsujino, K1
Agelidou, M; Emmanouilidis, C; Georgoulias, V; Hatzidaki, D; Karachaliou, N; Kontopodis, E; Kotsakis, A; Mountzios, G; Popis, E; Vardakis, N1
Bergman, JJ; Blom, RL; Busch, OR; Hulshof, MC; Klinkenbijl, JH; Reitsma, JB; Richel, DJ; van Berge Henegouwen, MI; van Heijl, M; Wilmink, JW1
Chen, XC; Jiang, N; Zhao, Y1
Chu, Z; Huang, M; Lu, G; Mao, Y; Yuan, B; Zhang, X; Zou, Y1
Polee, MB; Siersema, PD; Splinter, TA; Stoter, G; Tilanus, HW; Van der Gaast, A; Verweij, J1
de Boeck, G; de Bruijn, E; de Jonge, MJ; Dumez, H; Guetens, G; Highley, M; Louwerens, M; Mantel, M; Pawinsky, A; Planting, AS; Van Oosterom, AT; Verweij, J1
Friedrichs, K; Hölzel, F; Jänicke, F1
O'Brien, ME; Waters, JS1
Fukuda, M; Kasai, T; Kawabata, S; Kinoshita, A; Kohno, S; Nagashima, S; Nakamura, Y; Nakatomi, K; Oka, M; Soda, H; Takatani, H; Tsurutani, J1
Deckert, M; Hans, V; Kristof, RA; Neuloh, G; Schlegel, U; Schramm, J; Simon, M; Urbach, H1
Ackland, S; Hall, K; Levi, J; Lewis, C; Marx, G1
Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Malas, K; Mavroudis, D; Pallis, A; Samonis, G; Souglakos, J1
Chang, JY; Chen, LT; Chung, TR; Jan, CM; Liu, JM; Liu, TW; Shiah, HS; Whang-Peng, J; Wu, CW1
Andersson, H; Boman, K; Parö, G; Puistola, U; Ridderheim, M; Rosenberg, P; Sorbe, B1
Gerinière, L; Souquet, PJ1
Choma, D; Jacot, W; Pujol, JL; Quantin, X1
Besse, B; Spano, JP1
Gutierrez, M; Lhomme, C; Pautier, P1
Calvert, S; Greco, FA; Hainsworth, JD1
Blohmer, JU; Breidenbach, M; Göhring, UJ; König, E; Kurbacher, CM; Mallmann, P; Rein, DT; Schmidt, T; Schöndorf, T1
Bertucci, F; Chabannon, C; Conte, M; Genre, D; Gravis, G; Houvenaeghel, G; Maraninchi, D; Viens, P; Viret, F1
Budd, GT; Bukowski, RM; Elson, P; Hutson, TE; Mekhail, T; Olencki, T; Peereboom, D; Pelley, R; Srkalovic, G1
Anderson, SJ; Brown, A; Desai, AM; Kardinal, CG; Lembersky, BC; Mamounas, EP; Scholnik, AP; Smith, RE1
Morère, JF1
Azli, N; Campos, D; Chan, S; Falkson, C; Kennedy, I; Krzakowski, M; Leonard, R; Martin, M; Murawsky, M; Nabholtz, JM; Pienkowski, T; Pinter, T; Pouillart, P; Riva, A; Szanto, J; Vorobiof, D; Zaluski, J1
Cho, MJ; Kim, JS; Kim, Ki; Kim, SY1
Enomoto, K; Fukuda, M; Haga, S; Iino, Y; Ikeda, T; Shimizu, T; Taguchi, T1
Bonnet, R; Deppermann, KM; Gatzemeier, U; Hessler, S; Kaukel, E; Macha, HN; Reck, M; Ulm, K; von Pawel, J1
Baran, I; Coskun, H; Demiray, M; Evrensel, T; Gonullu, G; Kanat, O; Kurt, E; Manavoglu, O; Turan, OF; Zarifoglu, M1
Adamo, V; Alafaci, E; Ferraro, G; Laudani, A; Pergolizzi, S; Scimone, A; Sergi, C; Settineri, N; Spano, F; Spitaleri, G1
Catapano, CV; Freeman, KD; Green, MR; Mushtaq, C; Oakhill, G; Pacheco, D; Rocha Lima, CM; Sherman, CA1
Bonneterre, J; Catimel, G; Tubiana-Hulin, M1
Acito, L; Angiona, S; Bilancia, D; Di Costanzo, F; Gasperoni, S; Giustini, L; Manzione, L; Mazzoni, F1
Asmar, L; Dakhil, S; Friedland, DM; Gregurich, MA; Hollen, C1
Ang, P; Fong, KW; Foo, KF; Lee, KM; Leong, SS; Ong, YK; Tan, EH; Wee, J1
Anderson, IC; Eder, JP; Goffin, JR; Johnson, BE; Lynch, TJ; Shapiro, GI; Shipp, M; Skarin, AT; Supko, JG1
Chang, HK; Chen, MF; Chen, SC; Cheung, YC; Hsueh, S; Leung, WM; Lin, YC; Tsai, CS1
Athanasiadis, A; Athanasiadou, DC; Papakostoulis, T; Roussos, G; Stathopoulos, GP1
Kietpeerakool, C; Srisomboon, J; Suprasert, P1
Frgala, T; Odrázka, K; Petera, J; Spacek, J1
Abdel-Wahab, M; Abitbol, A; Hamilton, K; Lewin, A; Markoe, A; Troner, M1
Akerman, P; Barnett, JM; Cioffi, W; Cruff, D; Dipetrillo, T; Iannitti, D; Kennedy, T; Maia-Acuna, C; Martel, D; Miner, T; Remis, M; Safran, H1
Alderden-Los, C; Beijnen, JH; Rosing, H; Schellens, JH; Sharma, A; Veltkamp, SA1
Adjei, AA; Alberts, SR; Bruzek, L; Croghan, GA; Erlichman, C; Hanson, LJ; Jatoi, A; Ma, C; Mandrekar, SJ; Pitot, HC; Reid, JM; Tan, AD; Wright, JJ1
Cohen, RB; Cosgriff, TM; Eisenberg, PD; Hainsworth, JD; Healey, D; Langer, CJ; Liau, K; Madajewicz, S; Pierce, K; Simon, GR; Xu, H1
Vapattanawong, P1
Beeram, M; Hamilton, M; Hammond, LA; Hidalgo, M; Kreisberg, JI; Mita, MM; Nadler, P; Patnaik, A; Rowinsky, EK; Schwartz, G; Tolcher, AW; Wolf, J; Wood, D1
Armstrong, DK; Bookman, MA; Bristow, RE; McGuire, W; Schilder, JM1
Furlow, B1
Bafaloukos, D; Bakogiannis, C; Bamias, A; Boukovinas, I; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Kalofonos, HP; Kosmidis, PA; Makatsoris, T; Nicolaides, C; Samantas, E; Skarlos, D; Syrigos, K; Xiros, N1
Han, ES; Monk, BJ1
Chung, HC; Im, CK; Jeung, HC; Noh, SH; Rha, SY; Roh, JK; Yoo, NC1
Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N1
Argiris, A; Axelrod, R; Burtness, BA; Forastiere, AA; Manola, J1
Bayo, J; Bernabé, R; Jiménez, J; Lomas, M; Lopez-Ladrón, A; Moreno, A; Ruiz, M; Salvador, J; Valero, M; Vicente, D1
Arnold, A; Chen, E; Ellis, PM; Gauthier, I; Goss, G; Laurie, SA; Powers, J; Puchalski, TA; Robertson, J; Seymour, L; Shepherd, FA; Tu, D; Walsh, W1
Gelmon, KA1
Gomella, L; Greenberg, R; Hudes, GR; Khater, C; McAleer, C; Nathan, FE; Stern, C1
Bunn, PA; Kelly, KL1
Ajani, JA; Ilson, DH; Kelsen, DP1
Bentley, S; Bernard, S; Brecher, M; Graham, M; Johnston, C; Serody, J; Shea, T; Steagall, A; Vaisman, A; Wiley, J1
Bailey, NP; Boddy, A; Calvert, AH; Chapman, F; Gumbrell, L; Hughes, A; Humphreys, A; Robson, L; Siddiqui, N; Thomas, H1
Baselga, J; Crown, JP; Currie, V; Forsythe, P; Gilewski, TA; Hakes, TB; Hudis, CA; Reichman, BS; Seidman, AD; Yao, TJ1
Barrett, S; Crown, J; Currie, V; Gilewski, T; Gollub, M; Hudis, C; Lepore, J; Seidman, AD; Tiersten, A; Yao, TJ1
Groshen, S; Jeffers, S; Morris, M; Muderspach, L; Muggia, F; Roman, L; Russell, C; Uziely, B1
Bell, DR; Bishop, JF; Friedlander, M; Goldstein, D; Levi, JA; Millward, MJ; Olver, IN; Rischin, D; Smith, JG; Toner, GC1
Barnes, CS; Cowan, KH; Denicoff, AM; Goldspiel, BR; Gossard, MR; Kohler, DR; McCabe, M; Noone, MH; O'Shaughnessy, JA; Tolcher, AW; Zujewski, J1
Crump, M; Eisenhauer, E; Fisher, B; Latreille, J; Shepherd, FA; Stewart, D; Tomiak, E1
Burris, HA1
Alberts, DS; Brooks, DJ1
Bauknecht, T; Bochtler, H; Diergarten, K; du Bois, A; Lück, HJ; Meerpohl, HG; Möbus, V1
Kerkhofs, L; Kok, TC; Splinter, TA; van der Gaast, A; Vos, R1
Baselga, J; Currie, V; Fennelly, D; Gilewski, T; Hellmann, S; Holmes, F; Hortobagyi, G; Hudis, C; Maickel, N; Moynahan, M; Norton, L; Raptis, G; Riccio, L; Seidman, A; Sklarin, N; Surbone, A; Uhlenhopp, M; Usakewicz, J; Yao, TJ1
Bowling, K; Chen, TL; Donehower, RC; Duerr, M; Grochow, LB; Kennedy, MJ; Noe, D; Rowinsky, EK; Sartorius, S; Zahurak, ML1
Agelidou, M; Androulakis, N; Apostolopoulou, F; Dimopoulos, AM; Georgoulias, V; Hatzidaki, D; Heras, P; Kakolyris, S; Kourousis, C; Mavromanolakis, E; Papadakis, E; Papadimitriou, C; Tzannes, S; Vlachonicolis, J; Vossos, A1
Diergarten, K; Hanauske, AR; Heinrich, B; Herzog, M; Kau, R; Kemmerich, M; Laubenbacher, C; Quasthoff, S; Theiss, F; Thödtmann, F1
Androulakis, N; Bahlitzanakis, N; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Kamilaki, M; Kotsakis, A; Koukouraki, S; Koukourakis, MI; Kourousis, C1
Canfield, VA; Geyer, CE; Goodwin, DK; Green, SJ; Martino, S; Meyers, FJ; Moinpour, CM; O'Sullivan, J; Osborne, CK1
Chan, AT; Chiu, SK; Johnson, PJ; Leung, TW; Mok, TS; Yeo, W; Yu, P1
Anagnostopoulos, A; Diakomanolis, E; Dimopoulos, MA; Fountzilas, G; Giannakoulis, N; Gika, D; Moulopoulos, LA; Papadimitriou, CA; Sarris, K; Voulgaris, Z1
Agelidou, A; Androulakis, N; Apostolopoulou, F; Bouros, D; Dimopoulos, MA; Georgoulias, V; Hatzakis, K; Kakolyris, S; Kalbakis, K; Kotsakis, A; Kouroussis, C; Papadakis, E; Papadimitriou, C; Vardakis, N; Vlachonicolis, J1
Biesma, B; Fokkema, E; Groen, HJ; Kwa, B; Postmus, PE; Smit, EF; van Putten, JW1
Bagiella, E; Balog, J; Benson, M; Fine, R; Heitjan, D; Judge, T; Macarthur, RB; O'Connor, J; Olsson, CA; Petrylak, DP; Pfaff, C; Sawczuk, I; Shelton, G; Zuech, N1
Bianco, AR; Carlomagno, C; Casella, G; De Placido, G; De Placido, S; Ferrari, E; Fiorentino, R; Iodice, F; Lauria, R; Maffeo, A; Morabito, A; Perrone, F; Pignata, S; Ricchi, P; Tramontana, S; Varriale, E1
Agelaki, S; Androulakis, N; Dimou, T; Georgoulias, V; Giannakakis, T; Hatzidaki, D; Kakolyris, S; Mavroudis, D; Parashos, M; Sarra, E; Vlachonikolis, J; Ziras, N1
Adenis, A; Armand, JP; Baille, P; Blanc, C; Bonneterre, J; Clouet, P; de Forni, M; Dembak, M; Ducreux, M; Lebecq, A; Lefresne-Soulas, F; Rougier, P1
Barbieri, F; Bearz, A; Ceresoli, GL; Favaretto, A; Frustaci, S; Ghiotto, C; Oniga, F; Paccagnella, A; Schiavon, S; Villa, E1
Atkinson, R; Coleman, R; Crawford, M; Cruickshank, M; Eggleton, P; Fleming, D; Graham, J; Kaye, SB; Parkin, D; Paul, J; Reed, NS; Vasey, PA1
Aletti, G; Beatrice, S; Carnelli, M; Ferrari, A; Frigerio, L; Garavaglia, E; Mangili, G1
Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Mavroudis, D; Souglakos, J; Tsavaris, N; Tsiafaki, P1
Agelaki, S; Androulakis, N; Bania, E; Chainis, K; Georgoulias, V; Kakolyris, S; Kalofonos, C; Kouroussis, C; Papadakis, E; Rapti, A; Sarra, E; Toubis, M; Tsiafaki, X; Vardakis, N1
Allen, D; Davison, J; Gates, P; Neesham, D; Planner, R; Prince, HM; Quinn, M; Rischin, D1
Beijnen, JH; Duchin, K; Koopman, FJ; Lieverst, J; Malingré, MM; Rosing, H; Schellens, JH; Swart, M; ten Bokkel Huinink, WW; van Tellingen, O1
Burstein, HJ; Winer, EP1
De Giorgi, U; Marangolo, M; Papiani, G; Rosti, G1
Buijs, D; Gelderblom, H; Nooter, K; Ouwens, L; Sparreboom, A; Stoter, G; van Zomeren, DM; Verweij, J1
Abratt, RP; Chasen, MR; Cronje, N; Fourie, L; Hacking, D; McMichael, G; Rapoport, BL; Vorobiof, DA1
Bol, CJ; Brouwer, E; de Vries, R; Eskens, FA; Nooter, K; Palmer, PA; Sparreboom, A; van der Gaast, A; van Zuylen, L; Verweij, J1
Choi, YH; Hong, DS; In, KH; Jeong, TJ; Kim, HK; Kim, JS; Kim, YH; Lee, KS; Lee, SN; Lee, YY; Nam, E; Park, HS1
Baronius, W; Bokemeyer, C; Haag, C; Hartmann, JT; Hempel, V; Honecker, F; Kanz, L; Kollmannsberger, C; Quietzsch, D; Schroeder, M; Spott, C1
Domon, H; Fujimoto, S; Fujimoto, T; Fujino, T; Hareyama, H; Ishizaki, Y; Kaneuchi, M; Kawaguchi, I; Minobe, S; Sakuragi, N; Sato, C; Yamaguchi, T; Yamamoto, R; Yoshiaki, K1
Belleguic, C; Blanchon, F; Coste, E; Fournel, P; Le Caer, H; Léna, H; Pérol, M; Pham, E; Robinet, G; Schuller-Lebeau, MP; Thomas, P; Vergnenègre, A; Vernejoux, JM1
Depisch, D; Fiebiger, W; Gedlicka, C; Kornek, GV; Lang, F; Lenauer, A; Raderer, M; Scheithauer, W; Schneeweiss, B; Schüll, B1
Armstrong, DK; Donehower, RC; Ettinger, DS; Grumbine, FC; McGuire, WP; Rosenshein, NB; Rowinsky, EK1

Reviews

15 review(s) available for paclitaxel and Hematologic Diseases

ArticleYear
S-1 combined with paclitaxel may benefit advanced gastric cancer: Evidence from a systematic review and meta-analysis.
    International journal of surgery (London, England), 2019, Volume: 62

    Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Hematologic Diseases; Humans; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Analysis; Tegafur

2019
Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials.
    Actas urologicas espanolas, 2014, Volume: 38, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Combined Modality Therapy; Docetaxel; Epirubicin; Epothilones; Estramustine; Fatigue; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Orchiectomy; Paclitaxel; Peripheral Nervous System Diseases; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine

2014
Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.
    Cancer treatment reviews, 2015, Volume: 41, Issue:10

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Docetaxel; Gastrointestinal Diseases; Hematologic Diseases; Humans; Neurotoxicity Syndromes; Paclitaxel; Pharmacogenetics; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Receptor, EphA5; Receptor, EphA6; Taxoids; Tubulin

2015
Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials.
    Breast cancer research : BCR, 2008, Volume: 10, Issue:5

    Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Fatigue; Feasibility Studies; Female; Fluorouracil; Gastrointestinal Diseases; Germany; Hematologic Diseases; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine

2008
Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:13

    Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Female; Hematologic Diseases; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids

2002
The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).
    British journal of cancer, 2002, Aug-27, Volume: 87, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Europe; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome; United Kingdom; Vinblastine; Vinorelbine

2002
[Combinations of platinum salts and gemcitabine in the treatment of non-small-cell lung cancer].
    Bulletin du cancer, 2002, Volume: 89 Spec No

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Reproducibility of Results; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine

2002
[Platinum-free gemcitabine-based combinations: an alternative to conventional chemotherapy of non-small-cell lung cancers?].
    Bulletin du cancer, 2002, Volume: 89 Spec No

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine

2002
[Gemcitabine and breast cancer].
    Bulletin du cancer, 2002, Volume: 89 Spec No

    Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine

2002
[Gemicitabine in the treatment of epithelial ovarian cancer].
    Bulletin du cancer, 2002, Volume: 89 Spec No

    Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematologic Diseases; Humans; Multicenter Studies as Topic; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prodrugs; Remission Induction; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine

2002
Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix.
    International journal of radiation oncology, biology, physics, 2003, Apr-01, Volume: 55, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brachytherapy; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Dose Fractionation, Radiation; Female; Follow-Up Studies; Hematologic Diseases; Humans; Hysterectomy; Life Tables; Lymphatic Irradiation; Lymphatic Metastasis; Middle Aged; Nausea; Neoplasm Metastasis; Paclitaxel; Radiation Injuries; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Retrospective Studies; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms

2003
Bevacizumab in the treatment of ovarian cancer.
    Expert review of anticancer therapy, 2007, Volume: 7, Issue:10

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Female; Hematologic Diseases; Humans; Intestinal Perforation; Multicenter Studies as Topic; Neovascularization, Pathologic; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Salvage Therapy; Vascular Endothelial Growth Factor A

2007
Optimal use of docetaxel (Taxotere): maximizing its potential.
    Anti-cancer drugs, 1996, Volume: 7 Suppl 2

    Topics: Antineoplastic Agents, Phytogenic; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Docetaxel; Hematologic Diseases; Humans; Paclitaxel; Taxoids

1996
New combinations with Herceptin in metastatic breast cancer.
    Oncology, 2001, Volume: 61 Suppl 2

    Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine

2001
The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients.
    Haematologica, 2002, Volume: 87, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Etoposide; Europe; Forecasting; Gastrointestinal Diseases; Germinoma; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Hepatic Veno-Occlusive Disease; Humans; Ifosfamide; Kidney Diseases; Male; Multicenter Studies as Topic; Neoplasms, Second Primary; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Salvage Therapy; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome

2002

Trials

91 trial(s) available for paclitaxel and Hematologic Diseases

ArticleYear
A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer.
    International journal of clinical oncology, 2019, Volume: 24, Issue:12

    Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Prospective Studies; Treatment Outcome

2019
Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology).
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:5

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Chemoradiotherapy, Adjuvant; Endometrial Neoplasms; Endometrium; Feasibility Studies; Female; Follow-Up Studies; Germany; Hematologic Diseases; Humans; Incidence; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Quality of Life; Survival Analysis

2013
Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.
    Journal of gastrointestinal cancer, 2014, Volume: 45, Issue:3

    Topics: Adenocarcinoma; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Catheter-Related Infections; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Fatigue; Feasibility Studies; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Infusions, Parenteral; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Tegafur; Treatment Outcome

2014
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:5

    Topics: Activation, Metabolic; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Induction; Esophageal Neoplasms; Fatigue; Female; Gene Expression Regulation, Neoplastic; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Paclitaxel; Pancreatic Neoplasms; Prodrugs; Thymidine Phosphorylase; Treatment Outcome; Up-Regulation; Young Adult

2015
A phase 1 study evaluating the pharmacokinetics and preliminary efficacy of veliparib (ABT-888) in combination with carboplatin/paclitaxel in Japanese subjects with non-small cell lung cancer (NSCLC).
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzimidazoles; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Eruptions; Drug Synergism; Female; Hematologic Diseases; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Radiography; Salvage Therapy; Tumor Burden

2015
Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial.
    The Lancet. Oncology, 2016, Volume: 17, Issue:8

    Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemoradiotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Nervous System Diseases; Paclitaxel; Prognosis; Quality of Life; Radiotherapy, Adjuvant; Survival Rate

2016
A phase II study of carboplatin and paclitaxel for recurrent or metastatic head and neck cancer.
    Anti-cancer drugs, 2009, Volume: 20, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Follow-Up Studies; Head and Neck Neoplasms; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Peripheral Nervous System Diseases; Remission Induction; Treatment Outcome

2009
A phase I trial of dose-dense (biweekly) carboplatin combined with paclitaxel and pegfilgrastim: a feasibility study in patients with untreated Stage III and IV ovarian, tubal or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2010, Volume: 118, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Polyethylene Glycols; Recombinant Proteins

2010
Adjuvant dose-dense doxorubicin plus cyclophosphamide followed by dose-dense nab-paclitaxel is safe in women with early-stage breast cancer: a pilot study.
    Breast cancer research and treatment, 2011, Volume: 125, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Staging; Nervous System Diseases; Paclitaxel; Pilot Projects; Polyethylene Glycols; Recombinant Proteins; Time Factors; Treatment Outcome; United States

2011
Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Endpoint Determination; Female; Half-Life; Hematologic Diseases; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Pyrroles; Sunitinib; Treatment Outcome

2011
Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: a phase II multicenter study of the Hellenic Oncology Research Group.
    Lung cancer (Amsterdam, Netherlands), 2012, Volume: 77, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Salvage Therapy; Small Cell Lung Carcinoma; Treatment Outcome

2012
Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Diarrhea; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Nervous System Diseases; Paclitaxel; Survival Analysis; Treatment Outcome

2002
The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors.
    Anti-cancer drugs, 2002, Volume: 13, Issue:6

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Area Under Curve; Biotransformation; Chromatography, High Pressure Liquid; Deoxycytidine; Docetaxel; Drug Interactions; Female; Gemcitabine; Half-Life; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids

2002
Phase I and pharmacokinetic study of paclitaxel and irinotecan for patients with advanced non-small cell lung cancer.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel

2002
Phase I study of docetaxel plus ifosfamide in patients with advanced cancer.
    British journal of cancer, 2002, Oct-07, Volume: 87, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Ifosfamide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Taxoids

2002
Phase I study of weekly paclitaxel and liposomal doxorubicin in patients with advanced solid tumours.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:15

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxorubicin; Female; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Treatment Outcome

2002
A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
    Oncology, 2002, Volume: 63, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids

2002
Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum.
    Acta oncologica (Stockholm, Sweden), 2002, Volume: 41, Issue:5

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cimetidine; Clemastine; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Hypersensitivity; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Injections, Intravenous; Life Tables; Middle Aged; Muscular Diseases; Nervous System Diseases; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Premedication; Salvage Therapy; Survival Analysis; Treatment Outcome

2002
Paclitaxel and mitoxantrone in the treatment of metastatic breast cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
    Cancer investigation, 2002, Volume: 20, Issue:7-8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Middle Aged; Mitoxantrone; Paclitaxel; Survival Rate

2002
Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer: a phase I study.
    Gynecologic oncology, 2002, Volume: 87, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Uterine Cervical Neoplasms

2002
Intensive sequential dose dense chemotherapy with stem cell support as first-line treatment in advanced ovarian carcinoma: a phase II study.
    Bone marrow transplantation, 2002, Volume: 30, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Disease-Free Survival; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Life Tables; Mesna; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Peripheral Nervous System Diseases; Pilot Projects; Prognosis; Recombinant Proteins; Remission Induction; Survival Analysis; Treatment Outcome

2002
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
    Cancer, 2003, Jan-01, Volume: 97, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome

2003
Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Clinical breast cancer, 2002, Volume: 3, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Cause of Death; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome

2002
Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Mar-15, Volume: 21, Issue:6

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Health Status; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome; Ventricular Dysfunction, Left

2003
Phase I study of docetaxel and cyclophosphamide in patients with advanced or recurrent breast cancer.
    Breast cancer (Tokyo, Japan), 2003, Volume: 10, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Docetaxel; Drug Therapy, Combination; Female; Hematologic Diseases; Humans; Incidence; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids

2003
Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer.
    Journal of the National Cancer Institute, 2003, Aug-06, Volume: 95, Issue:15

    Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Proportional Hazards Models; Risk Factors; Survival Analysis; Treatment Outcome; Vincristine

2003
Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: a single center randomized study.
    Medical oncology (Northwood, London, England), 2003, Volume: 20, Issue:3

    Topics: Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cytoprotection; Female; Heart Diseases; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Prospective Studies; Protective Agents

2003
Paclitaxel and cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma.
    Oral oncology, 2004, Volume: 40, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cisplatin; Drug Therapy, Combination; Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Treatment Outcome

2004
Paclitaxel, epirubicin and cyclophosphamide combination in first-line treatment of metastatic breast cancer: a dose escalation study.
    Oncology, 2004, Volume: 66, Issue:3

    Topics: Adult; Aged; Anemia; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Hematologic Diseases; Hospitalization; Humans; Middle Aged; Neutropenia; Paclitaxel; Stroke Volume; Survival Analysis; Thrombocytopenia; Treatment Outcome; Ventricular Function, Left

2004
Paclitaxel and mitoxantrone in metastatic breast cancer: a phase II trial of the Italian Oncology Group for Cancer Research.
    Cancer investigation, 2004, Volume: 22, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiomyopathies; Chemotherapy, Adjuvant; Female; Hematologic Diseases; Humans; Middle Aged; Mitoxantrone; Paclitaxel; Survival Analysis; Treatment Outcome; Ventricular Function, Left

2004
A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer.
    Cancer investigation, 2004, Volume: 22, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carboplatin; Carcinoma; Combined Modality Therapy; Dexamethasone; Diphenhydramine; Disease-Free Survival; Drug Administration Schedule; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hyperglycemia; Life Tables; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Premedication; Survival Analysis; Treatment Outcome; Urologic Neoplasms; Urothelium

2004
Chemo-radiotherapy for stage III unresectable non-small cell lung cancer long-term results of a prospective study.
    Respiratory medicine, 2004, Volume: 98, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Esophagitis; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome

2004
Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, May-01, Volume: 11, Issue:9

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Hematologic Diseases; Humans; Hydroxamic Acids; Infusions, Intravenous; Lung Neoplasms; Male; Metabolic Clearance Rate; Metalloendopeptidases; Middle Aged; Nausea; Paclitaxel; Treatment Outcome

2005
Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma.
    Onkologie, 2005, Volume: 28, Issue:6-7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Comorbidity; Epirubicin; Feasibility Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Risk Assessment; Risk Factors; Severity of Illness Index; Taiwan; Treatment Outcome

2005
Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase I study.
    Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:6

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Outpatients; Paclitaxel; Survival Rate

2005
External beam radiotherapy and high-dose brachytherapy combined with cisplatin and paclitaxel in patients with advanced cervical carcinoma.
    Gynecologic oncology, 2005, Volume: 99, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Hematologic Diseases; Humans; Middle Aged; Paclitaxel; Retrospective Studies; Survival Rate; Uterine Cervical Neoplasms

2005
Quality-of-life assessment after hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable and/or unresectable head and neck squamous cell carcinoma.
    American journal of clinical oncology, 2005, Volume: 28, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Disease-Free Survival; Dose Fractionation, Radiation; Drug Eruptions; Esophageal Stenosis; Female; Fluorouracil; Follow-Up Studies; Gastrostomy; Head and Neck Neoplasms; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Radiotherapy, Adjuvant; Surveys and Questionnaires; Survival Rate

2005
Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study.
    American journal of clinical oncology, 2005, Volume: 28, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome

2005
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:2

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Boronic Acids; Bortezomib; Carboplatin; Disease Progression; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Treatment Outcome

2007
A phase I/randomized phase II, non-comparative, multicenter, open label trial of CP-547,632 in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC).
    Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:1

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Gastrointestinal Diseases; Half-Life; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Thiazoles; Treatment Outcome; Urea

2007
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Dec-15, Volume: 12, Issue:24

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Skin

2006
A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2007, Volume: 105, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Recombinant Proteins; Topotecan

2007
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cimetidine; Deoxycytidine; Dexamethasone; Diphenhydramine; Female; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Ondansetron; Paclitaxel; Premedication; Proportional Hazards Models

2008
A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:2

    Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Hematologic Diseases; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Analysis

2008
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Estrogens; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Paclitaxel; Peripheral Nervous System Diseases; Tamoxifen

2008
A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Epothilones; Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Recurrence; Salvage Therapy; Survival Analysis; Taxoids

2008
Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Disease Progression; Female; Gastrointestinal Diseases; Genes, erbB-2; Half-Life; Hematologic Diseases; Humans; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Trastuzumab

2008
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institut
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor Receptor-2

2008
Biweekly paclitaxel in the treatment of patients with metastatic breast cancer.
    Seminars in oncology, 1995, Volume: 22, Issue:5 Suppl 12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Middle Aged; Paclitaxel; Premedication; Treatment Outcome

1995
Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.
    Seminars in oncology, 1995, Volume: 22, Issue:5 Suppl 12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Fatigue; Hematologic Diseases; Hormones; Humans; Male; Nausea; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome

1995
A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer: a University of Colorado Cancer Center study.
    Seminars in oncology, 1995, Volume: 22, Issue:5 Suppl 12

    Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Premedication; Taxoids; Treatment Outcome

1995
The activity of paclitaxel in gastrointestinal tumors.
    Seminars in oncology, 1995, Volume: 22, Issue:5 Suppl 12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Neoplasms; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Male; Middle Aged; Paclitaxel; Prognosis; Survival Rate

1995
A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer.
    Seminars in oncology, 1995, Volume: 22, Issue:5 Suppl 12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Paclitaxel; Peripheral Nervous System Diseases

1995
Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.
    Seminars in oncology, 1995, Volume: 22, Issue:5 Suppl 12

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Creatinine; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Kidney Function Tests; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel

1995
Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:5

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance; Female; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Peripheral Nervous System Diseases; Treatment Outcome

1995
Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bayes Theorem; Bone Neoplasms; Breast Neoplasms; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Remission Induction; Salvage Therapy

1995
Paclitaxel (Taxol) in heavily pretreated ovarian cancer: antitumor activity and complications.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:9

    Topics: Adult; Aged; Bacterial Infections; Disease-Free Survival; Drug Administration Schedule; Drug Resistance; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Premedication; Risk Factors; Survival Analysis

1994
Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:1

    Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Drug Hypersensitivity; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Paclitaxel; Survival Rate; Treatment Outcome

1996
Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:1

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Cyclophosphamide; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Hypersensitivity; Equipment Failure; Erythrocyte Transfusion; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematuria; Home Infusion Therapy; Humans; Mesna; Middle Aged; Neoplasm Metastasis; Paclitaxel

1996
Phase I study of paclitaxel (Taxol) and ifosfamide in previously untreated patients with advanced non-small-cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel

1996
A phase I study of etoposide phosphate plus paclitaxel.
    Seminars in oncology, 1996, Volume: 23, Issue:6 Suppl 13

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Organophosphorus Compounds; Paclitaxel

1996
Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Dose-Response Relationship, Drug; Feasibility Studies; Female; Hematologic Diseases; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome

1997
A phase I dose finding study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced esophageal cancer.
    Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Female; Hematologic Diseases; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome

1997
Phase II study of semisynthetic paclitaxel in metastatic breast cancer.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:13

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome

1997
Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:2

    Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel

1998
First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Severity of Illness Index; Survival Rate; Taxoids; Treatment Outcome

1998
Clinical phase II evaluation of paclitaxel in combination with cisplatin in metastatic or recurrent squamous cell carcinoma of the head and neck.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Female; Head and Neck Neoplasms; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome

1998
Weekly docetaxel and concomitant boost radiotherapy for non-small cell lung cancer. A phase I/II dose escalation trial.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:6

    Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Hypersensitivity; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy; Taxoids; Treatment Outcome

1998
Expanded phase II trial of paclitaxel in metastatic breast cancer: a Southwest Oncology Group study.
    Breast cancer research and treatment, 1998, Volume: 51, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Drug Hypersensitivity; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Middle Aged; Neuromuscular Diseases; Paclitaxel; Pain Measurement; Palliative Care; Survival Analysis; Treatment Failure

1998
A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:13

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Hematologic Diseases; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Prospective Studies; Survival Analysis; Treatment Outcome

1998
Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:3

    Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nervous System Diseases; Paclitaxel; Survival Analysis; Uterine Cervical Neoplasms

1999
Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Paclitaxel; Survival Analysis; Taxoids

1999
Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Resistance; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis

1999
Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:3

    Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Estramustine; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Middle Aged; Paclitaxel; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids

1999
A phase I study of paclitaxel and epirubicin, without and with filgrastim, for the treatment of platinum-resistant advanced ovarian cancer.
    Oncology, 1999, Volume: 56, Issue:4

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Leukocyte Count; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Recombinant Proteins; Treatment Outcome

1999
Docetaxel in combination with carboplatin for the treatment of advanced non-small cell lung carcinoma: a multicentre phase I study.
    European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids

2000
A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma.
    European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:8

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Docetaxel; Female; France; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome

2000
Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:11

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fever; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Survival Analysis; Treatment Outcome

2000
Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer.
    British journal of cancer, 2001, Volume: 84, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Constipation; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Fatigue; Female; Hematologic Diseases; Humans; Middle Aged; Nausea; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vomiting

2001
Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: first feasibility study.
    Gynecologic oncology, 2001, Volume: 81, Issue:1

    Topics: Aged; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Diarrhea; Drug Administration Schedule; Drug Eruptions; Endometrial Neoplasms; Feasibility Studies; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation Injuries; Radiation-Sensitizing Agents; Radiodermatitis; Radiotherapy; Radiotherapy, Adjuvant; Risk Factors

2001
Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Rate

2001
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
    Lung cancer (Amsterdam, Netherlands), 2001, Volume: 32, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome

2001
Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
    Gynecologic oncology, 2001, Volume: 81, Issue:2

    Topics: Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan

2001
The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel.
    Anti-cancer drugs, 2001, Volume: 12, Issue:4

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carcinoma, Small Cell; Cyclosporine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Premedication; Stomach Neoplasms; Uterine Cervical Neoplasms; Uterine Neoplasms

2001
Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:4

    Topics: Aged; Antineoplastic Agents, Phytogenic; Ascitic Fluid; Biological Availability; Female; Gastrointestinal Diseases; Glycerol; Hematologic Diseases; Humans; Injections, Intraperitoneal; Injections, Intravenous; Mesothelioma; Middle Aged; Ovarian Neoplasms; Paclitaxel

2002
Malignant pleural mesothelioma: a phase II trial with docetaxel.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:3

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma; Docetaxel; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Mesothelioma; Middle Aged; Paclitaxel; Pleural Neoplasms; Survival Rate; Taxoids

2002
Phase II study of docetaxel and cisplatin combination chemotherapy in metastatic or unresectable localized non-small-cell lung cancer.
    International journal of clinical oncology, 2002, Volume: 7, Issue:2

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome

2002
Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
    Anti-cancer drugs, 2002, Volume: 13, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Survival Rate; Time Factors

2002
A phase I/II study of carboplatin and paclitaxel in patients with epithelial ovarian cancer.
    Japanese journal of clinical oncology, 2002, Volume: 32, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel

2002
Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:5

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Follow-Up Studies; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Reference Values; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine

2002
Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer.
    British journal of cancer, 2002, Jun-17, Volume: 86, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Male; Middle Aged; Paclitaxel; Stomach Neoplasms; Survival Rate; Treatment Outcome

2002

Other Studies

31 other study(ies) available for paclitaxel and Hematologic Diseases

ArticleYear
Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
    Bulletin du cancer, 2021, Volume: 108, Issue:3

    Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Digestive System Diseases; Docetaxel; Fatigue; Female; Fluorouracil; Hematologic Diseases; Humans; Male; Middle Aged; Nail Diseases; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Taxoids; Tunisia

2021
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
    Gynecologic oncology, 2021, Volume: 161, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; BRCA1 Protein; BRCA2 Protein; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase I as Topic; Female; Genes, BRCA1; Genes, BRCA2; Hematologic Diseases; Humans; Middle Aged; Multicenter Studies as Topic; Ovarian Neoplasms; Paclitaxel; Prospective Studies

2021
Chemoradiotherapy by intensity-modulated radiation therapy with simultaneous integrated boost in locally advanced or oligometastatic non-small-cell lung cancer-a two center experience.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2021, Volume: 197, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Cone-Beam Computed Tomography; Female; Follow-Up Studies; Four-Dimensional Computed Tomography; Hematologic Diseases; Humans; Lung Neoplasms; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Positron Emission Tomography Computed Tomography; Progression-Free Survival; Radiation Injuries; Radiation Pneumonitis; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Retrospective Studies; Tumor Burden; Vinorelbine

2021
Is macrocytosis a potential biomarker of the efficacy of dose-dense paclitaxel-carboplatin combination therapy in patients with epithelial ovarian cancer?
    Anti-cancer drugs, 2017, Volume: 28, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Erythrocytes, Abnormal; Female; Hematologic Diseases; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Retrospective Studies

2017
Comparative study of radiotherapy plus erlotinib versus chemoradiotherapy for elderly patients with esophageal cancer: a propensity score-matched analysis.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2017, Sep-01, Volume: 30, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Hematologic Diseases; Humans; Male; Neoplasm Staging; Paclitaxel; Patient Compliance; Propensity Score; Radiotherapy, Conformal; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate

2017
Radiation Dose to the Thoracic Vertebral Bodies Is Associated With Acute Hematologic Toxicities in Patients Receiving Concurrent Chemoradiation for Lung Cancer: Results of a Single-Center Retrospective Analysis.
    International journal of radiation oncology, biology, physics, 2018, 03-01, Volume: 100, Issue:3

    Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Etoposide; Female; Hematologic Diseases; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Organs at Risk; Paclitaxel; Probability; Radiation Dosage; Retrospective Studies; ROC Curve; Small Cell Lung Carcinoma; Thoracic Vertebrae

2018
Gemcitabine/nab-paclitaxel for pediatric relapsed/refractory sarcomas.
    Pediatric blood & cancer, 2018, Volume: 65, Issue:9

    Topics: Adolescent; Albumins; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Humans; Infections; Kaplan-Meier Estimate; Male; Paclitaxel; Recurrence; Salvage Therapy; Sarcoma; Young Adult

2018
Liposomal paclitaxel induces fewer hematopoietic and cardiovascular complications than bioequivalent doses of Taxol.
    International journal of oncology, 2018, Volume: 53, Issue:3

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cardiovascular Diseases; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compounding; Drug Liberation; Drug Screening Assays, Antitumor; Female; Glycerol; Hematologic Diseases; Humans; Liposomes; Male; Mice; Mice, Inbred ICR; Mice, SCID; Neutropenia; Paclitaxel; Therapeutic Equivalency; Tissue Distribution

2018
Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
    Gynecologic oncology, 2019, Volume: 154, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carboplatin; Cohort Studies; Cystadenocarcinoma, Serous; Female; Genes, BRCA1; Genes, BRCA2; Genetic Predisposition to Disease; Germ-Line Mutation; Hematologic Diseases; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retrospective Studies

2019
Risk factors for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia over time: assessment of monocyte count and baseline clinical parameters.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:5

    Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Case-Control Studies; Doxorubicin; Female; Hand-Foot Syndrome; Hematologic Diseases; Humans; Leukocyte Count; Male; Middle Aged; Monocytes; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols; Retrospective Studies; Sarcoma; Stomatitis; Thymus Neoplasms; Young Adult

2015
Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer.
    International journal of radiation oncology, biology, physics, 2016, Jan-01, Volume: 94, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Hematologic Diseases; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Radiation Dosage; Radiation Tolerance; Regression Analysis; Thoracic Vertebrae; Thrombocytopenia

2016
Hematological toxicity of carboplatin for gynecological cancer according to body mass index.
    European journal of clinical pharmacology, 2016, Volume: 72, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Female; Genital Neoplasms, Female; Hematologic Diseases; Humans; Middle Aged; Overweight; Paclitaxel

2016
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
    British journal of cancer, 2016, 09-06, Volume: 115, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Substitution; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Ontario; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Sepsis; Treatment Outcome

2016
Myelosuppression by chemotherapy in obese patients with gynecological cancers.
    Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Genital Neoplasms, Female; Hematologic Diseases; Humans; Ideal Body Weight; Japan; Middle Aged; Obesity; Paclitaxel; Retrospective Studies; Taxoids; Thinness; Young Adult

2016
Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer.
    British journal of cancer, 2016, 09-06, Volume: 115, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Capecitabine; Chemoradiotherapy; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gastrectomy; Gastrointestinal Diseases; Hematologic Diseases; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome

2016
Thermoreversible liposomal poloxamer gel for the delivery of paclitaxel: dose proportionality and hematological toxicity studies.
    Die Pharmazie, 2008, Volume: 63, Issue:6

    Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Body Burden; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Gels; Hematologic Diseases; Injections, Intravenous; Injections, Subcutaneous; Leukocyte Count; Liposomes; Male; Neutrophils; Paclitaxel; Rats; Rats, Sprague-Dawley

2008
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
    Anti-cancer drugs, 2009, Volume: 20, Issue:3

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Hypertension; Infusions, Intravenous; Letrozole; Mastectomy; Middle Aged; Nitriles; Paclitaxel; Prognosis; Proteinuria; Radiotherapy, Adjuvant; Triazoles

2009
Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy?
    BJOG : an international journal of obstetrics and gynaecology, 2010, Volume: 117, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Hematologic Diseases; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel

2010
Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011, Volume: 6, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Ethnicity; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Review Literature as Topic

2011
Neoadjuvant chemoradiotherapy followed by esophagectomy does not increase morbidity in patients over 70.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2013, Volume: 26, Issue:5

    Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagectomy; Female; Hematologic Diseases; Hospital Mortality; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Retrospective Studies; Survival Rate

2013
Analysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2013, Volume: 21, Issue:3

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Surface Area; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Creatinine; Female; Hematologic Diseases; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Retrospective Studies; Risk Factors; Sex Factors

2013
Synergetic toxicity of DATR, a recombinant soluble human TRAIL mutant, in combination with traditional chemotherapeutics in rats.
    Regulatory toxicology and pharmacology : RTP, 2012, Volume: 64, Issue:3

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Urea Nitrogen; Camptothecin; Female; Hematologic Diseases; Humans; Irinotecan; Kidney; Liver; Male; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Polyenes; Rats; Rats, Sprague-Dawley; TNF-Related Apoptosis-Inducing Ligand

2012
Combined surgery, radiation, and PCV chemotherapy for astrocytomas compared to oligodendrogliomas and oligoastrocytomas WHO grade III.
    Journal of neuro-oncology, 2002, Volume: 59, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cisplatin; Cohort Studies; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Staging; Oligodendroglioma; Paclitaxel; Prospective Studies; Radiotherapy; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; World Health Organization

2002
[New data presented at ASCO 2002 concerning non-small cell bronchial cancers].
    Revue de pneumologie clinique, 2002, Volume: 58, Issue:5 Pt 2

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine

2002
A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
    Cancer, 2004, Jun-15, Volume: 100, Issue:12

    Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; DNA Topoisomerases, Type I; Drug Administration Schedule; Etoposide; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Lymphocytes; Male; Middle Aged; Neoplasms; Paclitaxel; Topotecan

2004
Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2005, Volume: 88, Issue:3

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cross-Sectional Studies; Fallopian Tube Neoplasms; Female; Genital Neoplasms, Female; Hematologic Diseases; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome

2005
A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:1

    Topics: Administration, Oral; Adult; Antineoplastic Agents, Phytogenic; Area Under Curve; Capsules; Central Nervous System Diseases; Chemistry, Pharmaceutical; Cyclosporine; Female; Gastrointestinal Diseases; Half-Life; Hematologic Diseases; Humans; Immunosuppressive Agents; Injections, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Polymers

2007
A comparative study on hematological effects of carboplatin plus cyclophosphamide and carboplatin plus paclitaxel chemotherapy for the first line treatment of epithelial ovarian cancer.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2006, Volume: 89, Issue:9

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cyclophosphamide; Cystadenocarcinoma, Mucinous; Cystadenocarcinoma, Serous; Female; Hematologic Diseases; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies

2006
Toxic effects differ in combination treatment.
    The Lancet. Oncology, 2007, Volume: 8, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colony-Stimulating Factors; Docetaxel; Doxorubicin; Drug Therapy, Combination; Female; Hematologic Diseases; Humans; Paclitaxel; Peripheral Nervous System Diseases; Taxoids

2007
Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:8

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Biological Availability; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Female; Follow-Up Studies; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Paclitaxel; Quinolines; Taxoids

2002
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.
    Annals of internal medicine, 1989, Aug-15, Volume: 111, Issue:4

    Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Arrhythmias, Cardiac; Cisplatin; Drug Evaluation; Epilepsy, Tonic-Clonic; Female; Hematologic Diseases; Humans; Joint Diseases; Muscular Diseases; Ovarian Neoplasms; Paclitaxel; Pain; Peripheral Nervous System Diseases

1989